Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
作者： S. Siena , A. Sartore-Bianchi , S. Marsoni , H.I. Hurwitz , S.J. McCall
关键词: Internal medicine 、 Genetic testing 、 Colorectal cancer 、 Chemotherapy 、 Immunotherapy 、 Oncogene 、 Progression-free survival 、 Biopsy 、 Medicine 、 Biomarker (medicine) 、 Oncology
摘要: … growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target … biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 …
annalsofoncology.org
oup.com
elsevier.com
sci-hub.se 参考文章(75)
B Schuell, T Gruenberger, W Scheithauer, Ch Zielinski, F Wrba, HER 2/neu protein expression in colorectal cancer. BMC Cancer. ,vol. 6, pp. 123- 123 ,(2006) , 10.1186/1471-2407-6-123
Lena-Christin Conradi, Hanna Styczen, Thilo Sprenger, Hendrik A. Wolff, Claus Rödel, Manuel Nietert, Kia Homayounfar, Jochen Gaedcke, Julia Kitz, Recca Talaulicar, Heinz Becker, Michael Ghadimi, Peter Middel, Tim Beissbarth, Josef Rüschoff, Torsten Liersch, Frequency of HER-2 positivity in rectal cancer and prognosis. The American Journal of Surgical Pathology. ,vol. 37, pp. 522- 531 ,(2013) , 10.1097/PAS.0B013E318272FF4D
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Sharadah Essapen, Hilary Thomas, Margaret Green, Corrine De Vries, Martin Cook, Christopher Marks, Clare Topham, Helmout Modjtahedi, The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters International Journal of Oncology. ,vol. 24, pp. 241- 248 ,(2004) , 10.3892/IJO.24.2.241
S. Krege, S. Krege, Chemotherapie fortgeschrittener urologischer Tumoren Onkologie. ,vol. 26, pp. 13- 17 ,(2003) , 10.1159/000074740
Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M Comoglio, Alberto Bardelli, Livio Trusolino, None, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. ,vol. 1, pp. 508- 523 ,(2011) , 10.1158/2159-8290.CD-11-0109
Humberto A. Rossi, Qin Liu, Barbara Banner, Chung C. Hsieh, Louis Savas, Diane Savarese, The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer. Cancer Journal. ,vol. 8, pp. 268- 275 ,(2002) , 10.1097/00130404-200205000-00011
Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, Monica Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Domenico Amoroso, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone, Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer The New England Journal of Medicine. ,vol. 371, pp. 1609- 1618 ,(2014) , 10.1056/NEJMOA1403108
An Na Seo, Yoonjin Kwak, Duck-Woo Kim, Sung-Bum Kang, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee, HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression PLoS ONE. ,vol. 9, pp. e98528- ,(2014) , 10.1371/JOURNAL.PONE.0098528
Josef Rüschoff, Wedad Hanna, Michael Bilous, Manfred Hofmann, Robert Y Osamura, Frédérique Penault-Llorca, Marc van de Vijver, Giuseppe Viale, HER2 testing in gastric cancer: a practical approach Modern Pathology. ,vol. 25, pp. 637- 650 ,(2012) , 10.1038/MODPATHOL.2011.198